Loading
A phase 2 trial of Linperlisib in Follicular lymphoma, run by Shanghai YingLi Pharmaceutical Co. Ltd., with a status the registry has not verified recently.
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT04379167 by Shanghai YingLi Pharmaceutical Co. Ltd., with 140 participants planned, started 2020-12-30 and due to reach its primary completion in 2022-12-30. Interventions recorded: YY-20394. Conditions recorded: Follicular Lymphoma.
Linked to the drug Linperlisib because the registry names it among its interventions and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Linperlisib and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/